DrugPatentWatch Database Preview
VIIV Company Profile
» See Plans and Pricing
What is the competitive landscape for VIIV, and when can generic versions of VIIV drugs launch?
VIIV has twenty-two approved drugs.
There are fourteen US patents protecting VIIV drugs.
There are five hundred and ninety-two patent family members on VIIV drugs in sixty-nine countries and one hundred and sixty-six supplementary protection certificates in eighteen countries.
Summary for VIIV
| International Patents: | 592 |
| US Patents: | 14 |
| Tradenames: | 15 |
| Ingredients: | 14 |
| NDAs: | 22 |
| Patent Litigation for VIIV: | See patent lawsuits for VIIV |
| PTAB Cases with VIIV as patent owner: | See PTAB cases with VIIV as patent owner |
Drugs and US Patents for VIIV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | TIVICAY | dolutegravir sodium | TABLET;ORAL | 204790-001 | Aug 12, 2013 | RX | Yes | Yes | 9,242,986 | Start Trial | Y | Y | Start Trial | ||
| Viiv Hlthcare | TIVICAY | dolutegravir sodium | TABLET;ORAL | 204790-001 | Aug 12, 2013 | RX | Yes | Yes | 8,129,385 | Start Trial | Y | Y | Start Trial | ||
| Viiv Hlthcare | DOVATO | dolutegravir sodium; lamivudine | TABLET;ORAL | 211994-001 | Apr 8, 2019 | RX | Yes | Yes | 8,129,385 | Start Trial | Y | Y | Start Trial | ||
| Viiv Hlthcare | TRIUMEQ | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET;ORAL | 205551-001 | Aug 22, 2014 | RX | Yes | Yes | 9,242,986 | Start Trial | Y | Y | Start Trial | ||
| Viiv Hlthcare | SELZENTRY | maraviroc | SOLUTION;ORAL | 208984-001 | Nov 4, 2016 | RX | Yes | Yes | 7,576,097*PED | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | 4,828,838*PED | Start Trial |
| Viiv Hlthcare | TRIZIVIR | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 021205-001 | Nov 14, 2000 | 4,724,232 | Start Trial |
| Viiv Hlthcare | EPIVIR | lamivudine | TABLET;ORAL | 020564-001 | Nov 17, 1995 | 7,119,202*PED | Start Trial |
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | 6,180,639*PED | Start Trial |
| Viiv Hlthcare | RETROVIR | zidovudine | INJECTABLE;INJECTION | 019951-001 | Feb 2, 1990 | 4,837,208 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VIIV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 300 mg/150 mg/300 mg | ➤ Subscribe | 2011-03-22 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2011-11-22 |
| ➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-01-28 |
| ➤ Subscribe | Tablets | 700 mg | ➤ Subscribe | 2012-01-18 |
| ➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | 2007-09-27 |
| ➤ Subscribe | Tablets | 600 mg/50 mg/300 mg | ➤ Subscribe | 2017-08-14 |
| ➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2007-10-16 |
| ➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2011-08-08 |
| ➤ Subscribe | Oral Solution | 20 mg/ml | ➤ Subscribe | 2012-12-27 |
| ➤ Subscribe | Tablets | 150 mg/300 mg | ➤ Subscribe | 2007-06-26 |
| ➤ Subscribe | Tablets | 10 mg, 25 mg and 50 mg | ➤ Subscribe | 2017-08-14 |
International Patents for VIIV Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2744019 | Start Trial |
| Nicaragua | 200700069 | Start Trial |
| Norway | 20025227 | Start Trial |
| Colombia | 5090836 | Start Trial |
| Eurasian Patent Organization | 200700534 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VIIV Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2924034 | CA 2019 00024 | Denmark | Start Trial | PRODUCT NAME: DORAVIRINE, LAMIVUDINE AND DISOPROXIL; REG. NO/DATE: EU/1/18/1333 20181126 |
| 1663240 | 132016000024751 | Italy | Start Trial | PRODUCT NAME: ASSOCIAZIONE DI RILPIVIRINA E OGNI SUA FORMA TERAPEUTICAMENTE EQUIVALENTE PROTETTA DAL BREVETTO DI BASE, COME SALI DI ADDIZIONE FARMACEUTICAMENTE ACCETTABILI DI RILPIVIRINA, COMPRESO IL SUO SALE CLORIDRATO E EMTRICITABINA(EVIPLERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/737/001-002, 20111128 |
| 1663240 | CA 2016 00063 | Denmark | Start Trial | PRODUCT NAME: RILPIVIRINHYDROCHLORID OG TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/16/1112/001 20160623 |
| 0817637 | 23/2005 | Austria | Start Trial | PRODUCT NAME: KOMBINATION, UMFASSEND ABACAVIR BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES ESTERS ODER SOLVAT DAVON UND LAMIVUDIN BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES; REGISTRATION NO/DATE: EU/1/04/298/001, EU/1/04/298/002 20041217 |
| 1663240 | 222 6-2015 | Slovakia | Start Trial | PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
